艾伯维Abbvie Inc （ABBV） 2021年ESG行动报告「NYSE」.pdf

1、2021ESG Action ReportPeople.Passion.Possibilities.2021 ESG Action Report 3A Message from Our Chairman and CEOI am tremendously proud to introduce our 2021 Environment,Social&Governance(ESG)Action Report.This report reflects how we work with integrity and intention to advance patient health and a sus

2、tainable business that will deliver for our stakeholders for years to come.Powered by 50,000 employees around the globe,it is the responsibility and the privilege of everyone at AbbVie to support our communities,better our society and help the patients of today and tomorrow.Since AbbVie was founded

3、in 2013,we have worked to help patients suffering from a wide range of diseases and conditions.In 2020,our mission grew in scope and ability with the acquisition of Allergan and this past year was our first full year operating as a new combined company.Today,we are better positioned for continued gr

4、owth with leadership positions across the key therapeutic areas of immunology,oncology,neuroscience and eye care,and aesthetics.We have a proven track record of developing new innovative medicines that have made a remarkable impact for patients and will continue to change lives for years to come.Sin

5、ce our inception,we have achieved more than 21 major product or indication approvals.Through our pipeline of promising therapies,we anticipate the potential approval of more than a dozen new products or major indications over the next two years.These important milestones have the potential to help m

6、illions of additional patients.In addition to our medicines,we continued to deliver on our commitment to society.Together with our nonprofit partners,we advanced health and educational opportunities for underserved communities through our philanthropic commitments and continued to address the impact